A 35-year-old woman was diagnosed as triple-negative breast cancer(TNBC)by a core needle biopsy and referred to our hospital. She was diagnosed as cT2N3M1, cStage Ⅳ TNBC because of metastasis in the right axilla, supraclavicular and internal mammary lymph node, and the contralateral supraclavicular lymph node in addition to the primary tumor. No obvious visceral metastasis was observed. Immunohistochemical assay showed SP142 PD-L1-positive and CPS 10 or more by 22C3. The patient was started on atezolizumab+nab-paclitaxel(PTX)therapy, but progression disease(PD)was observed without obvious effect. Pembrolizumab+carboplatin+gemcitabine was started as second-line therapy, and the tumor achieved partial response(PR)but developed PD within 6 months. After that, she was administrated olaparib, but PD was observed, and after the therapy with PTX+bevacizumab, she is now treated with eribulin.